Treatment of Refractory Segmental Vitiligo and Alopecia Areata in a Child with Upadacitinib and NB-UVB: A Case Report

This case report describes the successful treatment of a nine-year-old child with co-occurring vitiligo and alopecia areata using upadacitinib in combination with narrowband UVB (NB-UVB). Conventional treatments like glucocorticoids often have adverse effects and limited efficacy. Upadacitinib, which targets overlapping pathogenic pathways in both conditions, led to a significant reduction in the areas affected by vitiligo and alopecia areata, achieving satisfactory results. This suggests a promising new approach for treating these autoimmune skin diseases in children.